BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ezobresib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ezobresib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04817007-3207@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ezobresib: Phase 1/2 readout est. (NCT04817007)
DESCRIPTION:Ezobresib\, phase 1/2.\nStudy: A Study to Assess the Safety and
  Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitin
 ib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)\nEstima
 ted primary completion: 31 August 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ezobresib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04817007
URL:https://assetmemo.bio/drug/ezobresib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
